Literature DB >> 9207232

Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth.

J Laterra1, E Rosen, M Nam, S Ranganathan, K Fielding, P Johnston.   

Abstract

We have shown previously that the multifunctional cytokine scatter factor/hepatocyte growth factor (SF/HGF) is elevated in human malignant gliomas. In this study we investigated how human SF/HGF expression affects the malignancy of the U373 human glioblastoma cell line in vivo and in vitro. Human SF/HGF gene transfer increased U373 glioblastoma tumorigenicity by > or = 20-fold and enhanced the growth rate of intracerebral U373 xenografts by 3- to 8-fold. SF/HGF expression had no effect on the proliferation of glioblastoma cell monolayers but increased their anchorage-independent colony formation in soft agar by 5- to 8-fold. These results are the first to show that SF/HGF expression by human glioblastoma cells enhances their growth dysregulation in vitro and malignancy in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207232     DOI: 10.1006/bbrc.1997.6853

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

1.  Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.

Authors:  C Rory Goodwin; Bachchu Lal; Xin Zhou; Sandra Ho; Shuli Xia; Alexandra Taeger; Jamie Murray; John Laterra
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

2.  Acyl-CoA synthetase VL3 knockdown inhibits human glioma cell proliferation and tumorigenicity.

Authors:  Zhengtong Pei; Peng Sun; Ping Huang; Bachchu Lal; John Laterra; Paul A Watkins
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

3.  The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival.

Authors:  Qing-le Liang; Zheng-ying Mo; Ping Wang; Xiao Li; Zhi-xiang Liu; Zhang-ming Zhou
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

Review 4.  Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas.

Authors:  A Besson; V W Yong
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

5.  Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation.

Authors:  Qiuhong Yang; Ryan Moulder K; Mark S Cohen; Shuang Cai; Laird M Forrest
Journal:  BAOJ Pharm Sci       Date:  2015-01-05

Review 6.  Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.

Authors:  Roger Abounader; John Laterra
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

7.  c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype.

Authors:  Yunqing Li; Angela Li; Martin Glas; Bachchu Lal; Mingyao Ying; Yingying Sang; Shuli Xia; Daniel Trageser; Hugo Guerrero-Cázares; Charles G Eberhart; Alfredo Quiñones-Hinojosa; Bjorn Scheffler; John Laterra
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

8.  An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Authors:  Fadila Guessous; Ying Zhang; Charles diPierro; Lukasz Marcinkiewicz; Jann Sarkaria; David Schiff; Sean Buchanan; Roger Abounader
Journal:  Anticancer Agents Med Chem       Date:  2010-01       Impact factor: 2.505

Review 9.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

10.  Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value.

Authors:  Roberto Garcia-Navarrete; Esperanza Garcia; Oscar Arrieta; Julio Sotelo
Journal:  J Neurooncol       Date:  2009-10-25       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.